UA77671C2 - Crystalline form of omeprazole - Google Patents

Crystalline form of omeprazole Download PDF

Info

Publication number: UA77671C2
Authority: UA; Ukraine
Prior art keywords: omeprazole; strong; differs; acetone; weak
Prior art date: 2001-04-25

Application number

UA2003109492A

Other languages

English (en)

Ukrainian (uk)

Inventor

Milae Natasa Hafner

Beleie Andreja Cisezerle

Original Assignee

Lek Tovarna Farmacevtskih

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-24

Publication date

2007-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA77671(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-24 Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih

2007-01-15 Publication of UA77671C2 publication Critical patent/UA77671C2/uk

Links

229960000381 omeprazole Drugs 0.000 title claims abstract description 139
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 138
238000000034 method Methods 0.000 claims abstract description 37
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 42
239000002904 solvent Substances 0.000 claims description 25
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 20
239000013078 crystal Substances 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 20
239000013543 active substance Substances 0.000 claims description 12
239000000843 powder Substances 0.000 claims description 12
238000010521 absorption reaction Methods 0.000 claims description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
238000001556 precipitation Methods 0.000 claims description 10
230000000717 retained effect Effects 0.000 claims description 10
238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 8
238000002441 X-ray diffraction Methods 0.000 claims description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
238000001816 cooling Methods 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
229910021529 ammonia Inorganic materials 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
238000001914 filtration Methods 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims 3
210000001035 gastrointestinal tract Anatomy 0.000 claims 3
239000000945 filler Substances 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 17
238000002360 preparation method Methods 0.000 abstract description 12
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
239000000047 product Substances 0.000 description 14
239000012535 impurity Substances 0.000 description 11
239000000243 solution Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000000354 decomposition reaction Methods 0.000 description 7
238000001228 spectrum Methods 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
238000001953 recrystallisation Methods 0.000 description 6
238000001802 infusion Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000004566 IR spectroscopy Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
238000012430 stability testing Methods 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 2
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000009858 acid secretion Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
229960003943 hypromellose Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940126409 proton pump inhibitor Drugs 0.000 description 2
239000000612 proton pump inhibitor Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
238000012360 testing method Methods 0.000 description 2
-1 their shape Substances 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001055 reflectance spectroscopy Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002834 transmittance Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

UA2003109492A 2001-04-25 2002-04-24 Crystalline form of omeprazole UA77671C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SI200100111A SI20875A (sl)	2001-04-25	2001-04-25	Kristalna oblika omeprazola
PCT/IB2002/001350 WO2002085889A1 (fr)	2001-04-25	2002-04-24	Forme cristalline d'omeprazole

Publications (1)

Publication Number	Publication Date
UA77671C2 true UA77671C2 (en)	2007-01-15

Family

ID=20432882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003109492A UA77671C2 (en)	2001-04-25	2002-04-24	Crystalline form of omeprazole

Country Status (26)

Country	Link
US (2)	US20040122056A1 (fr)
EP (1)	EP1390360B1 (fr)
JP (1)	JP4455815B2 (fr)
KR (1)	KR20030094358A (fr)
CN (1)	CN1531533B (fr)
AT (1)	ATE346063T1 (fr)
AU (1)	AU2002307892B2 (fr)
BG (1)	BG108287A (fr)
BR (1)	BR0209103A (fr)
CA (1)	CA2445251C (fr)
CZ (1)	CZ20032911A3 (fr)
DE (1)	DE60216273T2 (fr)
HR (1)	HRP20030853B1 (fr)
HU (1)	HUP0303928A2 (fr)
IL (1)	IL158561A0 (fr)
MX (1)	MXPA03009789A (fr)
NO (1)	NO20034715L (fr)
NZ (1)	NZ528917A (fr)
PL (1)	PL366471A1 (fr)
RS (1)	RS50880B (fr)
RU (1)	RU2286991C2 (fr)
SI (2)	SI20875A (fr)
SK (1)	SK13192003A3 (fr)
UA (1)	UA77671C2 (fr)
WO (1)	WO2002085889A1 (fr)
ZA (1)	ZA200307988B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) *	2004-07-02	2007-06-01	Esteve Quimica, S.A.	Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
WO2007008588A2 (fr) *	2005-07-07	2007-01-18	Dr. Reddy's Laboratories Ltd.	Omeprazole de forme b
ES2587980T3 (es) *	2006-02-22	2016-10-28	International Institute Of Cancer Immunology, Inc	Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
WO2008067037A2 (fr)	2006-10-05	2008-06-05	Santarus, Inc.	Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
EP2086543A2 (fr)	2006-10-27	2009-08-12	The Curators of the University of Missouri	Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
EA200900985A1 (ru)	2007-01-31	2009-12-30	Крка, Товарна Здравил, Д. Д., Ново Место	Способ получения оптически чистого омепразола
RU2339631C1 (ru) *	2007-04-12	2008-11-27	Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН)	Способ получения эзомепразола
WO2010134099A1 (fr)	2009-05-21	2010-11-25	Cadila Healthcare Limited	Procédé de préparation dans un récipient unique d'oméprazole
CN102786513A (zh) *	2011-05-18	2012-11-21	中国医学科学院药物研究所	奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) *	2011-09-07	2012-08-22	周晓东	一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) *	2012-08-02	2014-12-02	대화제약 주식회사	알-라베프라졸, 이의 금속염의 제조방법
IL312564A (en)	2021-11-05	2024-07-01	Cinclus Pharma Holding Ab Publ	Polymorphs of the hydrochloride salt of linfarezan glurate
JP2025532389A (ja)	2022-10-04	2025-09-29	ザビリュク，アルセニー	大動脈弁の石灰化の抑制
CN119320380B (zh) *	2024-10-14	2025-11-25	山东益康药业股份有限公司	奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途
CN119320381B (zh) *	2024-10-14	2025-12-12	山东益康药业股份有限公司	奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
DE69112917T2 (de) *	1990-06-15	1996-05-15	Merck & Co Inc	Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
SE510666C2 (sv) *	1996-12-20	1999-06-14	Astra Ab	Nya Kristallmodifikationer
SI20019A (sl) *	1998-07-13	2000-02-29	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) *	1998-08-11	2000-12-26	Merck & Co., Inc.	Omeprazole process and compositions thereof
UA72748C2 (en) *	1998-11-10	2005-04-15	Astrazeneca Ab	A novel crystalline form of omeprazole
AUPQ841800A0 (en) *	2000-06-28	2000-07-20	Biomolecular Research Institute Limited	Truncated egf receptor
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs

2001
- 2001-04-25 SI SI200100111A patent/SI20875A/sl not_active IP Right Cessation
2002
- 2002-04-24 CN CN028089553A patent/CN1531533B/zh not_active Expired - Lifetime
- 2002-04-24 SK SK1319-2003A patent/SK13192003A3/sk unknown
- 2002-04-24 KR KR10-2003-7013767A patent/KR20030094358A/ko not_active Ceased
- 2002-04-24 DE DE60216273T patent/DE60216273T2/de not_active Expired - Lifetime
- 2002-04-24 PL PL02366471A patent/PL366471A1/xx not_active Application Discontinuation
- 2002-04-24 MX MXPA03009789A patent/MXPA03009789A/es active IP Right Grant
- 2002-04-24 WO PCT/IB2002/001350 patent/WO2002085889A1/fr not_active Ceased
- 2002-04-24 CA CA2445251A patent/CA2445251C/fr not_active Expired - Lifetime
- 2002-04-24 RS YUP-840/03A patent/RS50880B/sr unknown
- 2002-04-24 AT AT02764081T patent/ATE346063T1/de active
- 2002-04-24 SI SI200230491T patent/SI1390360T1/sl unknown
- 2002-04-24 JP JP2002583416A patent/JP4455815B2/ja not_active Expired - Lifetime
- 2002-04-24 AU AU2002307892A patent/AU2002307892B2/en not_active Expired
- 2002-04-24 RU RU2003133213/04A patent/RU2286991C2/ru active
- 2002-04-24 IL IL15856102A patent/IL158561A0/xx unknown
- 2002-04-24 US US10/475,239 patent/US20040122056A1/en not_active Abandoned
- 2002-04-24 CZ CZ20032911A patent/CZ20032911A3/cs unknown
- 2002-04-24 NZ NZ528917A patent/NZ528917A/en unknown
- 2002-04-24 UA UA2003109492A patent/UA77671C2/uk unknown
- 2002-04-24 HR HR20030853A patent/HRP20030853B1/xx not_active IP Right Cessation
- 2002-04-24 EP EP02764081A patent/EP1390360B1/fr not_active Expired - Lifetime
- 2002-04-24 HU HU0303928A patent/HUP0303928A2/hu unknown
- 2002-04-24 BR BR0209103-8A patent/BR0209103A/pt not_active Application Discontinuation
2003
- 2003-10-14 ZA ZA200307988A patent/ZA200307988B/xx unknown
- 2003-10-21 NO NO20034715A patent/NO20034715L/no not_active Application Discontinuation
- 2003-10-24 BG BG108287A patent/BG108287A/bg unknown
2005
- 2005-10-12 US US11/248,461 patent/US7553856B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ20032911A3 (en)	2004-06-16
JP4455815B2 (ja)	2010-04-21
EP1390360B1 (fr)	2006-11-22
ZA200307988B (en)	2004-10-14
NO20034715L (no)	2003-12-10
SI1390360T1 (sl)	2007-04-30
CA2445251C (fr)	2011-01-04
JP2004526786A (ja)	2004-09-02
RS50880B (sr)	2010-08-31
YU84003A (sh)	2006-08-17
HRP20030853A2 (en)	2005-08-31
KR20030094358A (ko)	2003-12-11
US20040122056A1 (en)	2004-06-24
AU2002307892B2 (en)	2008-04-17
HUP0303928A2 (hu)	2004-03-01
DE60216273D1 (de)	2007-01-04
US20060079560A1 (en)	2006-04-13
MXPA03009789A (es)	2005-03-07
NZ528917A (en)	2006-02-24
CN1531533B (zh)	2012-07-18
BG108287A (bg)	2005-04-30
RU2286991C2 (ru)	2006-11-10
PL366471A1 (en)	2005-02-07
SI20875A (sl)	2002-10-31
IL158561A0 (en)	2004-05-12
CN1531533A (zh)	2004-09-22
BR0209103A (pt)	2004-07-13
RU2003133213A (ru)	2005-05-10
US7553856B2 (en)	2009-06-30
WO2002085889A1 (fr)	2002-10-31
EP1390360A1 (fr)	2004-02-25
DE60216273T2 (de)	2007-05-31
NO20034715D0 (no)	2003-10-21
HRP20030853B1 (en)	2011-11-30
ATE346063T1 (de)	2006-12-15
SK13192003A3 (sk)	2004-03-02
CA2445251A1 (fr)	2002-10-31

Publication	Publication Date	Title
UA77671C2 (en)	2007-01-15	Crystalline form of omeprazole
JP3377218B2 (ja)	2003-02-17	オメプラゾールナトリウム塩
JP3457945B2 (ja)	2003-10-20	オメプラゾールの新規な結晶形
RU2467012C2 (ru)	2012-11-20	Способ очистки стауроспорина и способ получения n-бензоилстауроспорина
AU2002307892A1 (en)	2003-04-17	Crystalline form of omeprazole
CA2738458A1 (fr)	2009-07-16	Formes solvatees de cristaux de (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benzimidazole
HU226766B1 (en)	2009-09-28	Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
EA028769B1 (ru)	2017-12-29	Фармацевтические композиции, содержащие рифаксимин и аминокислоты, способ их получения и их применение
CN115260193A (zh)	2022-11-01	用于治疗狂犬病的化合物及其方法
RU2263673C2 (ru)	2005-11-10	Алкоксизамещенные бензимидазольные соединения, содержащие их фармацевтические препараты и способ их применения
CZ272897A3 (cs)	1998-01-14	Způsob přípravy monohydrátu loracarbefu
KR20010107953A (ko)	2001-12-07	오메프라졸의 신규한 결정질 형태
CZ12566U1 (cs)	2002-09-02	Amlodipinhemimaleát a farmaceutický prostředek